Page 1

IDEXX Q2 2021 Earnings Highlights ( NASDAQ : IDXX ) Operating Profit $ 259M Revenue $ 826M Reported growth : Organic growth : CAG Diagnostics Recurring Organic Growth : CAG Revenue Reported growth : Organic growth : Net CAG Revenue CAG Diagnostics Recurring IDEXX VetLab® Consumables + 30 % + 25 % $ 746M + 32 % + 27 % Rapid Assay Products Reference Laboratory Dx and Consulting Services CAG Diagnostics Services and Accessories CAG Diagnostics Capital - Instruments Veterinary Software , Services and Diagnostic Imaging Systems + 26 % Catalyst Installed Base ( in thousands ) Q2 Revenue $ 661M $ 256M $ 84M $ 294M $ 27M $ 35M $ 49M GE 31.4 % of Revenue + 14 % year over year 31.1 32.8 35.1 370 38.5 39.8 41.5 439 45.1 46.0 47.6 49.6 51.0 52.6 YoY change in basis points : Reported Comparable Revenue Reported growth : Organic growth : Reported Growth year over year + 30 % + 31 % + 30 % + 28 % + 32 % + 86 % Water + 33 % IDEXX Premium Instruments Installed Base +110 bps +110 bps $ 37M + 32 % + 27 % Organic Growth year over year + 26 % + 26 % + 28 % + 25 % + 27 % + 78 % + 26 % Premium Hematology Installed Base ( in thousands ) 4 TOTAL + 11 % year over year 26.7 27.4 28.0 28.9 29.5 298 305 315 320 32.4 33.6 34.6 35.1 35.8 Diluted Earnings Per Share $ 2.34 Reported growth : Comparable growth : Q2 Premium Instrument Placements Revenue Reported growth : Organic growth : New and competitive Premium Hematology SediVue® Dx LPD WW Catalyst 1.975 1,246 1,119 662 3,756 + 36 % + 33 % $ 34M + 4 % -2 % North America 771 1,204 308 519 SediVue Installed Base ( in thousands ) 409 Intl 938 600 253 1,699 2,057 + 24 % year over year 4.6 5.2 5.9 6.6 7.1 7.6 82 89 9.3 9.6 10.0 10.7 11.311.9 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2018 2019 2020 2021 2018 2019 2020 2021 2018 2019 2020 2021 For full financial data , non - GAAP reconciliations and cautionary language regarding forward - looking statements , please refer to IDEXX's 2021 second quarter earnings release issued on July 30 , 2021 available at https://www.idexx.com/investors . Amounts presented may not recalculate due to rounding . Ⓒ2021 IDEXX Laboratories , Inc. All rights reserved . Contact : John Ravis , Investor Relations ( 207 ) 556-8155 . IDEXX